Stockscreener 앱 받기
4.25
4.71%
-0.22
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
Metric Analysis: Arbutus Biopharma Corp (ABUS)’s Key Ratios in the Limelight - The Dwinnex
Arbutus Biopharma Corp’s Banking’s 100-Day Moving Average at 3.43: Will the Stock Break Through? - The InvestChronicle
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 3.5% - MarketBeat
What was Arbutus Biopharma Corp (ABUS)’s performance in the last session? - US Post News
Analytical Lens: Exploring Arbutus Biopharma Corp (ABUS)’s Financial Story Through Ratios - The Dwinnex
Biopharma Layoff Tracker 2024: Connect Biopharma, BioMarin and More Cut Staff - BioSpace
Taking the lead: Arbutus Biopharma Corp (ABUS) - SETE News
Arbutus Biopharma (NASDAQ:ABUS) Sets New 12-Month High at $4.56 - MarketBeat
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year? - Yahoo Finance
Market Momentum Report: Arbutus Biopharma Corp (ABUS)’s Positive Close at 4.51 - The Dwinnex
Arbutus Biopharma (NASDAQ:ABUS) Price Target Increased to $7.00 by Analysts at Jefferies Financial Group - Defense World
Arbutus Biopharma (NASDAQ:ABUS) PT Raised to $7.00 - MarketBeat
Arbutus Biopharma Corp: Navigating a Turbulent Year, Up 3.34% from 52-Week Low - The InvestChronicle
ABUS’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Arbutus Biopharma to Present at Major Investor Conferences in New York - MyChesCo
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5% - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Hits New 12-Month High at $4.04 - MarketBeat
Nothing is Better Than Arbutus Biopharma Corp (ABUS) stock at the moment - SETE News
ABUS stock touches 52-week high at $3.98 amid robust gains - Investing.com
Arbutus to Participate in Two Upcoming Investor Conferences - Yahoo Finance
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Passes Above Two Hundred Day Moving Average of $3.14 - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average of $3.14 - Defense World
Quarterly Metrics: Quick and Current Ratios for Arbutus Biopharma Corp (ABUS) - The Dwinnex
Do investors need to be concerned about Arbutus Biopharma Corp (ABUS)? - US Post News
There is no doubt that Arbutus Biopharma Corp (ABUS) ticks all the boxes. - SETE News
Arbutus Biopharma Corp (ABUS) can make a big difference with a little luck - SETE News
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Arbutus Biopharma Corp (ABUS) stock analysis: A simple moving average approach - US Post News
California State Teachers Retirement System Decreases Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Vax Patent Battles Heat Up As Attention On Pandemic Wanes - Law360
Arbutus Biopharma (STU:I9DN) 9-Day RSI : 51.66 (As of Aug. 19, 2024) - GuruFocus.com
Price T Rowe Associates Inc. MD Buys 6,649 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
ABUS (Arbutus Biopharma) Inventory Turnover : 0.00 (As of Jun. 2024) - GuruFocus.com
ABUS (Arbutus Biopharma) Revenue : $10.06 Mil (TTM As of Jun. 2024) - GuruFocus.com
ABUS (Arbutus Biopharma) EV-to-Revenue : 55.66 (As of Aug. 18, 2024) - GuruFocus.com
ABUS (Arbutus Biopharma) Enterprise Value : $559.99 Mil (As of Aug. 17, 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Price-to-Owner-Earnings : (As of Aug. 17, 2024) - GuruFocus.com
Arbutus Biopharma (FRA:I9DN) 3-Year FCF Growth Rate : 8.40% (As of Jun. 2024) - GuruFocus.com
Arbutus Biopharma (FRA:I9DN) Forward Rate of Return (Yacktm - GuruFocus.com
Arbutus Biopharma (FRA:I9DN) 9-Day RSI : 53.15 (As of Aug. 17, 2024) - GuruFocus.com
Arbutus Biopharma (FRA:I9DN) Price-to-Free-Cash-Flow : N/A (As of Aug. 17, 2024) - GuruFocus.com
Arbutus Biopharma (FRA:I9DN) 14-Day RSI : 54.05 (As of Aug. 17, 2024) - GuruFocus.com
No sleep for the biotech bear: Restructurings abound in August - BioCentury
Arbutus Biopharma (FRA:I9DN) Debt-to-Equity : 0.01 (As of Jun. 2024) - GuruFocus.com
A stock that deserves closer examination: Arbutus Biopharma Corp (ABUS) - US Post News
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 6.1% - MarketBeat
It makes sense and dollars to buy Arbutus Biopharma Corp (ABUS) stock - SETE News
Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Raised to Hold at StockNews.com - Defense World
Market Insights: Arbutus Biopharma Corp (ABUS)’s Notable Drop of -3.04, Closing at 3.51 - The Dwinnex
Is Arbutus Biopharma Corp (ABUS) a good investment opportunity? - US Post News
Walleye Trading LLC Purchases Shares of 14,000 Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Arbutus and Genevant extend Moderna patent trial to 2025 - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) PT Raised to $5.00 - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Lowered by StockNews.com - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Downgraded by StockNews.com to Sell - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
JMP Securities Increases Arbutus Biopharma (NASDAQ:ABUS) Price Target to $5.00 - MarketBeat
Arbutus Biopharma Corp (ABUS) Q2 2024 Earnings Call Transcript H - GuruFocus.com
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2024 Earnings Call Transcript - Insider Monkey
Arbutus: Q2 Earnings Snapshot - New Haven Register
Arbutus slashes workforce by 40%, narrows hepatitis B cure efforts - The Business Journals
1.26%
1.94%
자본화:
|
볼륨(24시간):